# US 5,700,664 A · Mammalian cytokine, IL-11

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,700,664 A
- Document ID: US5700664A
- Status: Granted
- Kind: A
- Application number: 07/949,516
- Filed: 1992-11-19
- Granted: 1997-12-23
- Earliest claimed: 1989-11-22
- Assignees: Genetics Institute, Inc.
- Inventors: Yu-Chung Yang; Frances K. Bennett; Stephan R. Paul
- Web page: https://patentgrep.com/patent/US5700664A

## CPC

- A61K 38/2073: {IL-11}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 37/04: Immunostimulants
- C07K 14/5431: {IL-11}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A novel mammalian cytokine, IL-11, and processes for producing it are disclosed. IL-11 may be used in pharmaceutical preparations for stimulating and/or enhancing cells involved in the immune response and cells involved in the proper functioning of the hematopoietic system.

## Claims

### Claim 1

An isolated IL-11 having the amino acid sequence of SEQ ID NO: 2 and having one or more of the following characteristics:
(1) an apparent molecular weight under reducing conditions on SDS PAGE of approximately 20 kd;
(2) a calculated molecular weight of approximately 20 kd;
(3) biological activity in a T1165 assay;
(4) biological activity in a megakaryocyte colony forming assay in the presence of IL-3;
(5) biological activity on a B cell plaque forming assay.

### Claim 2

An isolated mammalian IL-11 comprising amino acids 22-199 of SEQ ID NO: 2.

### Claim 3 (depends on 2)

An IL-11 of claim 2 comprising the human sequence.

### Claim 4 (depends on 2)

An IL-11 of claim 2 produced by culturing a cell transformed with a DNA sequence encoding expression of said IL-11 polypeptide in operative association with an expression control sequence capable of directing the replication and expression of said IL-11, and recovering from the conditioned medium thereof said IL-11 protein.

### Claim 5 (depends on 2)

A process for producing a mammalian IL-11 comprising culturing a cell line transformed with a cDNA sequence encoding a mammalian IL-11 of claim 2 in operative association with an expression control sequence capable of directing the replication and expression of said IL-11.

### Claim 6 (depends on 2)

An isolated DNA coding for an IL-11 of claim 2.

### Claim 7 (depends on 6)

A cell transformed with a DNA of claim 6 in operative association with an expression control.

### Claim 8 (depends on 7)

A cell according to claim 7 comprising a mammalian or bacterial cell.

### Claim 9 (depends on 6)

A plasmid vector comprising a DNA of claim 6.

### Claim 10 (depends on 2)

A pharmaceutical composition comprising a mammalian IL-11 of claim 2 in a pharmaceutically effective vehicle.

### Claim 11 (depends on 2)

Homogeneous mammalian IL-11 of claim 2 having biological activity in the T1165 assay in the absence of IL-6.

### Claim 12 (depends on 2)

A method for increasing platelet formation comprising administering an effective amount of IL-11 of claim 2.

### Claim 13 (depends on 12)

The method of claim 12, wherein said IL-11 is administered intravenously.

### Claim 14 (depends on 2)

An injectable pharmaceutical composition for increasing platelet formation comprising an aqueous solution of IL-11 of claim 2 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 6)

A DNA which hybridizes under stringent conditions of 0.1 x SSC at 65.degree. C. to a DNA of claim 6.